Nebilet Hctz (Hydrochlorothiazide, Nebivolol)

Nebivolol blocks β1‑adrenergic receptors, reducing heart rate and contractility, and also promotes nitric‑oxide‑mediated vasodilation. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal tubule, increasing urine output and decreasing plasma volume. Together they lower peripheral resistance and cardiac output, producing a sustained antihypertensive effect.

The exact dose of Nebilet Hctz is determined by the prescribing clinician based on the patient’s blood‑pressure readings, overall health, and concomitant therapies. Physicians typically start with a low dose and adjust as needed to reach therapeutic goals while monitoring for safety.

Safety data for nebivolol and hydrochlorothiazide in pregnancy or lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nebilet Hctz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nebilet Hctz offers a dual mechanism—beta‑blockade plus diuresis—in a single tablet, which can simplify regimens compared with separate agents. Unlike some older β‑blockers, nebivolol adds nitric‑oxide‑mediated vasodilation, potentially improving tolerability. However, choice of therapy depends on individual patient factors, comorbidities, and physician preference.

Store Nebilet Hctz at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Nebilet Hctz is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a full glass of water and follow any specific timing instructions provided by their healthcare professional.

Serious adverse events can include severe electrolyte disturbances such as hyponatremia or hypokalemia, acute kidney injury, and marked bradycardia or heart block. Patients should be monitored for signs of these conditions, especially when initiating therapy or adjusting doses.

Nebilet Hctz is contraindicated in individuals with known hypersensitivity to nebivolol, hydrochlorothiazide, or any component of the formulation. It should also be avoided in patients with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and those with uncontrolled electrolyte imbalances or severe renal impairment.